Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudqvist, Nils-Petter, Avagyan, Manushak, Chand, Dhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Author‘s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627057/
https://www.ncbi.nlm.nih.gov/pubmed/37937212
http://dx.doi.org/10.1080/2162402X.2023.2275333
_version_ 1785131461741903872
author Rudqvist, Nils-Petter
Avagyan, Manushak
Chand, Dhan
author_facet Rudqvist, Nils-Petter
Avagyan, Manushak
Chand, Dhan
author_sort Rudqvist, Nils-Petter
collection PubMed
description Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.
format Online
Article
Text
id pubmed-10627057
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-106270572023-11-07 Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy Rudqvist, Nils-Petter Avagyan, Manushak Chand, Dhan Oncoimmunology Author‘s View Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types. Taylor & Francis 2023-11-05 /pmc/articles/PMC10627057/ /pubmed/37937212 http://dx.doi.org/10.1080/2162402X.2023.2275333 Text en © 2023 AGENUS INC. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Author‘s View
Rudqvist, Nils-Petter
Avagyan, Manushak
Chand, Dhan
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
title Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
title_full Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
title_fullStr Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
title_full_unstemmed Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
title_short Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
title_sort next-generation ctla-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
topic Author‘s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627057/
https://www.ncbi.nlm.nih.gov/pubmed/37937212
http://dx.doi.org/10.1080/2162402X.2023.2275333
work_keys_str_mv AT rudqvistnilspetter nextgenerationctla4targetingmoleculesandcombinationtherapypromisingstrategiesforimprovingcancerimmunotherapy
AT avagyanmanushak nextgenerationctla4targetingmoleculesandcombinationtherapypromisingstrategiesforimprovingcancerimmunotherapy
AT chanddhan nextgenerationctla4targetingmoleculesandcombinationtherapypromisingstrategiesforimprovingcancerimmunotherapy

Ejemplares similares